Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develop… Read more
Market Cap & Net Worth: Arcus Biosciences Inc (RCUS)
Arcus Biosciences Inc (NYSE:RCUS) has a market capitalization of $2.80 Billion ($2.80 Billion) as of March 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #5397 globally and #3193 in its home market, demonstrating a -3.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcus Biosciences Inc's stock price $22.59 by its total outstanding shares 123728536 (123.73 Million).
Arcus Biosciences Inc Market Cap History: 2018 to 2026
Arcus Biosciences Inc's market capitalization history from 2018 to 2026. Data shows growth from $1.33 Billion to $2.80 Billion (3.61% CAGR).
Index Memberships
Arcus Biosciences Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P Small-Cap 600 Index
SML
|
$1.36 Trillion | 0.04% | #300 of 602 |
Weight: Arcus Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arcus Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcus Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.14x
Arcus Biosciences Inc's market cap is 7.14 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.33 Billion | $8.35 Million | -$49.59 Million | 159.53x | N/A |
| 2019 | $1.25 Billion | $15.00 Million | -$75.93 Million | 83.31x | N/A |
| 2020 | $3.21 Billion | $78.00 Million | -$123.00 Million | 41.18x | N/A |
| 2021 | $5.01 Billion | $383.00 Million | $53.00 Million | 13.07x | 94.48x |
| 2022 | $2.56 Billion | $112.00 Million | -$267.00 Million | 22.85x | N/A |
| 2023 | $2.36 Billion | $117.00 Million | -$307.00 Million | 20.20x | N/A |
| 2024 | $1.84 Billion | $258.00 Million | -$283.00 Million | 7.14x | N/A |
Competitor Companies of RCUS by Market Capitalization
Companies near Arcus Biosciences Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Arcus Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Arcus Biosciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Arcus Biosciences Inc's market cap moved from $1.33 Billion to $ 2.80 Billion, with a yearly change of 3.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.80 Billion | -5.20% |
| 2025 | $2.95 Billion | +60.04% |
| 2024 | $1.84 Billion | -22.04% |
| 2023 | $2.36 Billion | -7.64% |
| 2022 | $2.56 Billion | -48.90% |
| 2021 | $5.01 Billion | +55.89% |
| 2020 | $3.21 Billion | +157.03% |
| 2019 | $1.25 Billion | -6.22% |
| 2018 | $1.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Arcus Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.80 Billion USD |
| MoneyControl | $2.80 Billion USD |
| MarketWatch | $2.80 Billion USD |
| marketcap.company | $2.80 Billion USD |
| Reuters | $2.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.